Grifols SA ADR(GRFS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:01 PM ET (Korea 10/29 05:01)
Full metrics table
| Index | - | P/E | 10.46 | EPS (ttm) | 0.77 | Insider Own | 0.06% | Shs Outstand | 258.2M | Perf Week | 8.07% |
| Market Cap | 2.09B | Forward P/E | 6.6 | EPS next Y | 26.31% | Insider Trans | - | Shs Float | 258.1M | Perf Month | 11.1% |
| Enterprise Value | 14.03B | PEG | 0.29 | EPS next Q | - | Inst Own | 56.42% | Short Float | 2.71% | Perf Quarter | -1.16% |
| Income | 0.53B | P/S | 0.24 | EPS this Y | 14.11% | Inst Trans | 3.77% | Short Ratio | 12.28 | Perf Half Y | 2.47% |
| Sales | 8.65B | P/B | 0.87 | EPS next 5Y | 22.9% | ROA | 2.28% | Short Interest | 6.99M | Perf YTD | -13.32% |
| Book/sh | 9.32 | P/C | 3.57 | EPS past 3/5Y | 27.36% -8.34% | ROE | 8.5% | 52W High | -18.13% ($9.90) | Perf Year | -13.41% |
| Cash/sh | 2.27 | P/FCF | 2.21 | Sales past 3/5Y | 10.04% 6.88% | ROIC | 3.38% | 52W Low | 16.45% ($6.96) | Perf 3Y | 3.38% |
| Dividend Est. | $0.25 (3.03%) | EV/EBITDA | 7.3 | EPS Y/Y TTM | 61.67% | Gross Margin | 36.98% | Volatility(W/M) | 2.36% 2.2% | Perf 5Y | -38.92% |
| Dividend TTM | 0.11 | EV/Sales | 1.62 | Sales Y/Y TTM | 6.84% | Oper. Margin | 16.23% | ATR (14) | 0.21 | Perf 10Y | -44.1% |
| Dividend Ex-Date | 2026/7/2 | Quick Ratio | 0.81 | EPS Q/Q | 34.78% | Profit Margin | 6.09% | RSI (14) | 68.73 | Recom | 2.67 |
| Dividend Gr. 3/5Y | - -8.05% | Current Ratio | 2.37 | Sales Q/Q | 1.65% | SMA20 | 7.58% ($7.53) | Beta | 0.77 | Target Price | $11.3 |
| Payout | 34.22% | Debt/Eq | 1.54 | Earnings | 2026/7/28 | SMA50 | 6.74% ($7.59) | Rel Volume | 1.7 | Prev Close | $8.1 |
| Employees | 25258 | LT Debt/Eq | 1.46 | EPS/Sales Surpr. | -26.24% -6.1% | SMA200 | 1.21% ($8) | Avg Volume(3M) | 0.57M | Price | $8.1 |
| IPO | 2011/6/2 | Option/Short | Yes/Yes | Trades | 5138 | Volume | 969,100 | Change | 0.06% |
🩸 A global pharmaceutical company that develops and manufactures plasma-derived therapies. It produces plasma protein therapeutics such as immunoglobulins, albumin, and coagulation factors extracted from human plasma, and also operates a worldwide plasma collection network along with a diagnostics business. The company has established itself as a pharmaceutical specialist in plasma medicines with a vertically integrated structure that spans from plasma collection to drug manufacturing.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Traded more than usual. That is 170% of its average volume.
GRFS earns at a steady pace
Of every $100 in sales, $16.23 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +14.1% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company expected to earn $100 next year, you would pay $660. Peers typically go for $1,513.
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -38.9%. The S&P 500 did +69% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 3.03% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 56.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #16 of 21 in the industry
Based on market cap of $2B.
GSK#13 GSK Plc ADR $98B PER 15.4 
BIIB#14 Biogen Inc $36B PER 43.2 
OGN#15 Organon & Co $4B PER 17.6 GRFS#16 Grifols SA ADR $2B PER 10.5 
AMRN#17 Amarin Corp ADR $269M PER - 
FAQ
What kind of company is GRFS?
GRFS belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of GRFS?
The market cap of GRFS is approximately $2.1B, ranking 2,029 within its sector.
Does GRFS pay dividends?
GRFS has a dividend yield of approximately 3.03%, with an annual dividend of $0.25.
What is the P/E ratio of GRFS?
GRFS has a P/E ratio of approximately 10.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for GRFS?
GRFS has recorded a 52-week high of $9.90 and a low of $6.96.
